The year 2020 has been a difficult year since the beginning of the Covid-19 pandemic which has got medical experts on the loop. This search for scientific solutions for virus and diseases includes psychological needs too. Psychedelics been mind altering drugs which researchers believe can unlock more potentials. LSD trials and clinical test perform has in 2020 brought the thought of possible legalization of the drug.

LSD (Lysergic acid diethylamide) is a part of a group of drugs known as psychedelics. It is also considered to be an empathogen, that is a drug that enhances feelings of empathy and connectedness. It is a synthetic chemical derived from a fungus that commonly infects rye.

LSD is also described as a ‘psychedelic’ (or mind-manifesting) drug because of the changes experienced to perception, mood and thought. When taken in high doses it reportedly distorts experiences of time and space in addition to producing visual hallucinations.

LSD as a treatment

Recent findings indicate that psychedelic drugs can affect the function and structure of the brain and promote neuron growth. Exactly how LSD affects the brain is complicated, but it seems to interact with multiple receptors, such as serotonin and dopamine.

The first companies developing medical treatments from psychedelic drugs like LSD, ketamine and the active ingredient in magic mushrooms are gearing up to list on Canadian stock exchanges.

Mind Medicine Inc., which is undertaking clinical trials of psychedelic-based drugs, intends to list on Toronto’s NEO Exchange by the first week of March, said JR Rahn, the company’s co-founder and co-chief executive officer. A NEO spokesman confirmed the listing, which is pending final approvals.

Clinical trials

For those who are still getting used to legal marijuana, the idea of publicly traded companies working with psychedelic drugs like MDMA and psilocybin, which is derived from magic mushrooms, may sound a bit out there.

Yet a growing number of companies are conducting clinical trials of psychedelic treatments for everything from depression to post-traumatic stress disorder, and some have recently received the blessing of the U.S. Food and Drug Administration. Royal psychedelics with its well furnish laboratories base in the United States took upon itself to make its market safer. Keeping the street safer by selling LSD in its safest form and conducting test to continue offering to our customers the best. See Royalpsychedelicsshop Tch. clinical test results after request. We are open to sharing our result but following the norms and needs.

The resurgent interest in LSD is building on studies conducted 40 years ago: primarily focusing on treating depression, post-traumatic stress disorder, drug dependency, and reducing anxiety in patients with a life-threatening disease. The role of LSD in improving mental health seems to be linked to a weakening or ‘dissolution’ of the ego, helping individuals see the ‘bigger picture’ beyond their personal problems. In 2020 the recent results keep confirming the thought and pushes the research further.